Hammerhead ribozyme specifically inhibits vascular endothelial growth factor gene expression in a human hepatocellular carcinoma cell line

Citation
F. Morino et al., Hammerhead ribozyme specifically inhibits vascular endothelial growth factor gene expression in a human hepatocellular carcinoma cell line, INT J ONCOL, 17(3), 2000, pp. 495-499
Citations number
30
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF ONCOLOGY
ISSN journal
10196439 → ACNP
Volume
17
Issue
3
Year of publication
2000
Pages
495 - 499
Database
ISI
SICI code
1019-6439(200009)17:3<495:HRSIVE>2.0.ZU;2-Z
Abstract
Hammerhead-type ribozymes are often utilized to suppress the expression of target genes. We evaluated the efficacy of an anti-vascular endothelial gro wth factor (VEGF) hammerhead-type ribozyme against GUC at exon 1 of the VEG F gene in a cell-free system (in vitro) as well as in the hepatocellular ca rcinoma cell line HLF (in vivo). The anti-VEGF ribozyme (alpha VRz) specifi cally cleaved synthetic VEGF RNA substrate, but not other triplet sequences of VEGF RNA substrate in vitro. When the aVRz was introduced into HLF cell s, the ribozyme suppressed not only VEGF mRNA level but also that of VEGF p rotein. These results suggest that this ribozyme selectively inhibits VEGF gene expression in human hepatocellular carcinoma cells.